Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
TEL AVIV, Israel, Nov. 23, 2016 -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced it will provide a corporate overview in a “fireside chat” format at the 28th Annual Piper Jaffray Healthcare Conference. The conference is being held on November 29-30, 2016, at Lotte New York Palace Hotel in New York City.
| Presentation Details | ||
| Event: | 28th Annual Piper Jaffray Healthcare Conference | |
| Date & Time: | Tuesday, November 29 @ 7:30am Eastern Time. | |
| Location: | Lotte New York Palace Hotel in New York City, Ballroom Hubbard 1 | |
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >200 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).
INVESTOR CONTACT: Michael Rice LifeSci Advisors, LLC (646) 597-6979
